Quick Read – BMY’s 4.39% yield is backed by 94 consecutive years of payments and a lean 41% payout ratio, making it a rare income stock for retirees. – A dovish Fed directly benefits BMY’s ~$49 billion debt stack, lowering refinancing costs and protecting cash available for…
areholders. – The dividend is rated safe, but future raises will stay modest unless legacy drug erosion remains within the guided range of 12 to 16 percent decline. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bristol Myers Squibb didn’t make the cut. Grab the names FREE today
With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion.
The question I want answered: is this payout actually safe? Dividend Snapshot Payout Ratios Leave Real Room to Breathe BMY paid out roughly $5.15 billion in dividends against FY2025 non-GAAP EPS of $6.15, putting the earnings payout ratio near 41%. Through nine months of 2025, operating cash flow hit $6.3 billion, comfortably above the ~$3.9 billion of dividends paid in the same window.